Journal Logo



Gkalea, V.1, 2; Gonthier, M.-C.1, 2, 3; Gendron, N.1, 2, 3; Mavoungou, S.4; Bourrienne, M.-C.1, 2, 3; Alhenc-Gelas, M.5; Pouplard, C.6; Tardy, B.7; Hezard, N.8; Huisse, M.-G.1; Eloy, P.4; Faille, D.1, 2, 3; Ajzenberg1, N.1, 2, 3

doi: 10.1097/01.HS9.0000564240.71382.3e
Poster Session II: Platelets disorders

1Hematology laboratory, Bichat Hospital

2Faculty of Medicine, Paris Diderot university


4Service de biostatistiques, Bichat Hospital

5Hematology laboratory, Georges Pompidou European Hospital, Paris

6Hematology laboratory, CHRU Tours, Tours

7Intensive care unit, CHU Saint-Etienne, Saint-Etienne

8Hematology laboratory, CHU Robert Debré, Reims, France

Back to Top | Article Outline


Early recognition of heparin-induced thrombocytopenia (HIT) is crucial because of increased risk of life threatening venous and/or arterial thrombosis. In case of positive immunoassay, HIT diagnosis has to be confirmed by functional assays detecting heparin-dependent platelet-activating antibodies (anti-PF4/H). Heparin-induced platelet activation test (HIPA) and serotonin release assay (SRA) are two functional assays that use washed platelets. SRA is considered the gold standard, but HIPA offers several advantages over SRA: it does not require radioactivity or specialized equipment and is less time consuming. HIPA closely correlates to SRA but 20 years after its first description, there is no additional published data regarding its diagnostic performances.

Back to Top | Article Outline


To evaluate HIPA performances compared to SRA in a retrospective cohort of patients suspected for HIT. Secondary objectives were to evaluate negative or positive cut-off criteria for HIPA and to identify clinical and/or biological factors associated with positive HIPA.

Back to Top | Article Outline


We retrospectively analyzed the medical records of 81 consecutive patients who were suspected for HIT in our center between October 2010 and October 2015. Clinical suspicion of HIT was based on otherwise unexplained fall of platelet count (>40%) 5 to 21 days after the initiation of heparin and/or the occurrence of any thrombotic event during heparin treatment. Patients with positive anti-PF4/H IgG immunoassay (Zymutest HIA IgG, Hyphen BioMed, France) who were tested by SRA and HIPA were included in this study. Anti-PF4/H IgG was positive when optical density was greater than 0.5 OD units. Patients with indeterminate SRA or HIPA results or who were tested with less than two and more than four platelet donors for the HIPA were excluded. SRA was considered positive when serotonin release was greater than 20% at 0.1 U/mL and/ or 0.5 IU/mL unfractionated heparin (UFH) and decreased by at least 50% at high UFH concentration (100 IU/mL). HIPA was considered positive when the suspension became transparent due to platelet aggregation with UFH 0.2 IU/ml and/or 0.5 IU/ml but not with UFH 48 IU/ml and when positive results were obtained with at least two platelet donors. HIPA was considered negative if negative results were obtained with four platelets donors. Positive percent agreement (PPA), negative percent agreement (NPA), overall percent agreement (OPA) and Cohen's kappa (κ) and their 95% confidence intervals (CI) were calculated.

Back to Top | Article Outline


HIPA and SRA results were compared in 47 patients fulfilling eligibility criteria. PPA and NPA were 83.8% (95% CI 71.9-95.7%) and 75.0% (95% CI 53.8-96.2%), respectively. The OPA was 81.1% (95% CI 78.4-83.8%; κ = 0.58, CI 0.33-0.80). Defining HIPA positive when positive results were obtained with two donors was associated with a higher NPA (80.0% versus 75.0%) with a minimal decrease of the PPA (81.3% versus 83.8%) compared to positive result with only one patient. No association was found between surgery, extracorporeal circulation, anti-PF4/H IgG titer, platelet count nadir or type of heparin and HIPA results.

Back to Top | Article Outline


HIPA showed a good performance against SRA when testing suspected HIT patients. A good concordance was found between the two assays. HIPA performance can be enhanced considering two positive results to establish HIT diagnosis and four negative results to rule out HIT diagnosis. HIPA appears to be an optional sensitive and specific functional assay for HIT diagnosis easy to handle without radioactivity and safety issues.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.